WO1999024026A3 - Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds - Google Patents

Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds Download PDF

Info

Publication number
WO1999024026A3
WO1999024026A3 PCT/JP1998/005042 JP9805042W WO9924026A3 WO 1999024026 A3 WO1999024026 A3 WO 1999024026A3 JP 9805042 W JP9805042 W JP 9805042W WO 9924026 A3 WO9924026 A3 WO 9924026A3
Authority
WO
WIPO (PCT)
Prior art keywords
apoptosis
treatment
disorders associated
glyoxylamide compounds
heterocyclic glyoxylamide
Prior art date
Application number
PCT/JP1998/005042
Other languages
French (fr)
Other versions
WO1999024026A2 (en
Inventor
Tatsurou Yagami
Nobuo Takasu
Original Assignee
Shionogi & Co
Tatsurou Yagami
Nobuo Takasu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co, Tatsurou Yagami, Nobuo Takasu filed Critical Shionogi & Co
Priority to EP98951749A priority Critical patent/EP1037630A2/en
Priority to JP2000520118A priority patent/JP2003522720A/en
Priority to CA002308269A priority patent/CA2308269A1/en
Priority to AU97630/98A priority patent/AU9763098A/en
Publication of WO1999024026A2 publication Critical patent/WO1999024026A2/en
Publication of WO1999024026A3 publication Critical patent/WO1999024026A3/en
Priority to US10/219,931 priority patent/US20030149000A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A method or composition is disclosed for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds.
PCT/JP1998/005042 1997-11-12 1998-11-10 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds WO1999024026A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP98951749A EP1037630A2 (en) 1997-11-12 1998-11-10 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
JP2000520118A JP2003522720A (en) 1997-11-12 1998-11-10 Method for treating apoptosis-related disease using N-heterocyclic glyoxamide compound
CA002308269A CA2308269A1 (en) 1997-11-12 1998-11-10 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
AU97630/98A AU9763098A (en) 1997-11-12 1998-11-10 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
US10/219,931 US20030149000A1 (en) 1998-11-10 2002-08-16 Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPPCT/JP97/04104 1997-11-12
PCT/JP1997/004104 WO1999024033A1 (en) 1997-11-12 1997-11-12 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US53078100A Continuation-In-Part 1998-11-10 2000-05-05

Publications (2)

Publication Number Publication Date
WO1999024026A2 WO1999024026A2 (en) 1999-05-20
WO1999024026A3 true WO1999024026A3 (en) 1999-07-15

Family

ID=14181471

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP1997/004104 WO1999024033A1 (en) 1997-11-12 1997-11-12 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
PCT/JP1998/005042 WO1999024026A2 (en) 1997-11-12 1998-11-10 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/004104 WO1999024033A1 (en) 1997-11-12 1997-11-12 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds

Country Status (5)

Country Link
EP (1) EP1037630A2 (en)
JP (1) JP2003522720A (en)
AU (1) AU9763098A (en)
CA (1) CA2308269A1 (en)
WO (2) WO1999024033A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011947A1 (en) * 1998-08-28 2000-03-09 Uropath Pty. Ltd. Method of diagnosis of prostate cancer
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
WO2001014378A1 (en) * 1999-08-23 2001-03-01 Shionogi & Co., Ltd. PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES
DE19962300A1 (en) * 1999-12-23 2001-06-28 Asta Medica Ag New N-benzylindolyl glyoxylic acid derivatives are useful as antitumor agents
WO2002000255A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cancer
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
JP2004522713A (en) * 2000-11-17 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー Method for treating p38 kinase-related diseases and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
RS92004A (en) * 2002-04-23 2006-12-15 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
PE20060421A1 (en) 2004-08-12 2006-06-01 Bristol Myers Squibb Co PROCEDURE FOR PREPARING A COMPOUND OF PYRROLOTRIAZINE ANILINE AS KINASE INHIBITORS
US20150025105A1 (en) * 2012-02-09 2015-01-22 Praveen Rao Perampalli Nekkar Indolizine derivatives
US11713374B2 (en) * 2020-03-05 2023-08-01 The Boeing Company Schiff base oligomers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017183A1 (en) * 1993-12-23 1995-06-29 Eli Lilly And Company Use of pla2 inhibitors as treatment for alzheimer's disease
EP0675110A1 (en) * 1994-04-01 1995-10-04 Eli Lilly And Company 1H-Indole-3-glyoxylamide sPLA2 inhibitors
WO1996003383A1 (en) * 1994-07-21 1996-02-08 Eli Lilly And Company INDOLIZINE sPLA2 INHIBITORS
WO1996040982A1 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Therapeutic inhibition of phospholipase a2 in neurodegenerative disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017183A1 (en) * 1993-12-23 1995-06-29 Eli Lilly And Company Use of pla2 inhibitors as treatment for alzheimer's disease
EP0675110A1 (en) * 1994-04-01 1995-10-04 Eli Lilly And Company 1H-Indole-3-glyoxylamide sPLA2 inhibitors
WO1996003383A1 (en) * 1994-07-21 1996-02-08 Eli Lilly And Company INDOLIZINE sPLA2 INHIBITORS
WO1996040982A1 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Therapeutic inhibition of phospholipase a2 in neurodegenerative disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DRAHEIM ET AL.: "Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2. 3. Indole-3-glyoxamides", J. MED. CHEM., vol. 39, no. 26, 1996, pages 5159 - 5175, XP002073103 *
GONZALO J A ET AL: "LINOMIDE, A NOVEL IMMUNOMODULATOR THAT PREVENTS DEATH IN FOUR MODELS OF SEPTIC SHOCK", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, no. 9, 1 January 1993 (1993-01-01), pages 2372 - 2374, XP000568243 *

Also Published As

Publication number Publication date
WO1999024026A2 (en) 1999-05-20
JP2003522720A (en) 2003-07-29
EP1037630A2 (en) 2000-09-27
WO1999024033A1 (en) 1999-05-20
AU9763098A (en) 1999-05-31
CA2308269A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
AU5482398A (en) New substituted pyrazole derivatives for the treatment of cardiovascular disorders
AU8569698A (en) Method of inducing apoptosis by reducing the level of thiamin
AU2001247474A1 (en) Compounds for the treatment of psychiatric or substance abuse disorders
AU5362696A (en) Compounds and methods for the dectection of t. cruzi infection
AU4209197A (en) Process for the control of weeds
WO1999024026A3 (en) Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
AU6910600A (en) Methods for the treatment of mental disorders
AU1323795A (en) Overflow preventer
AU4939497A (en) Cpp32 inhibitors for regulating apoptosis
AU7287598A (en) Process for the conversion of hydrocarbons
AU4674797A (en) Phenylalaninol derivatives for the treatment of central nervous system disorders
AU1865497A (en) Method for the treatment of a liquid
AU5038299A (en) Process for the biocidal treatment of surfaces
ZA982454B (en) Method for treatment of chronic bronchitis using indole compounds.
AU7671198A (en) Methods for the inhibition of neuronal activity by local delivery of adenosi ne
AU1697197A (en) Immunoconjugate for the treatment of aids
AU3187595A (en) Compounds for the treatment of restenosis
AU3460797A (en) Bicyclic compounds for controlling micturition
AU2172899A (en) Aminosulphonylbenzamide derivatives as modulators of the activity of neuronal calcium channels
IL136720A0 (en) Indole derivatives useful a.o. for the treatment of osteoporosis
CY2392B1 (en) Method for the preparation of alpha-bromolactam derivatives.
AU7080798A (en) Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
AUPM456894A0 (en) Treatment for gastric disorders
AU2651197A (en) Processes for the preparation of pyrimidine compound
AU1994697A (en) Process for the control of pests

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2308269

Country of ref document: CA

Ref country code: CA

Ref document number: 2308269

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09530781

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998951749

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998951749

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998951749

Country of ref document: EP